新医学Issue(6)：391-394,4.DOI:10.3969/g.issn.0253-9802.2015.06.011
化学治疗交替吉非替尼治疗 EGFR 突变阳性的晚期非小细胞肺癌的疗效和安全性
Efficacy and safety of alternate chemotherapy with gefitinib in treatment of advanced non-small cell lung cancer with positive mutation of EGFR
江冠铭 1贾筠 1陈镜塘 1吴依芬 1谭钦全 1卢志斌1
作者信息
- 1. 523029 东莞，东莞市人民医院肿瘤内科
- 折叠
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of alternate chemotherapy with first-line gefitinib in treating advanced non-small cell lung cancer with positive mutation of epidermal growth factor receptor (EGFR).Methods Forty patients first diagnosed with advanced non-small cell lung cancer with positive EGFR mutation were enrolled.They were scheduled to receive gemcitabine at a dose of 1 000 mg/m2 on days 1 and 8,cisplatin 75 mg/m2 or carboplatin AUC 5 on day 1 and gefitinib 250 mg/day from days 1 5 to 28.One cycle of therapy endured for 28 days.After 4 ~6 cycles of chemotherapy based upon individual situ-ation,gefitinib was administered orally at a dose of 250 mg/day until disease progression or intolerable toxicity occurred.Clinical efficacy and toxicity were observed.Results The median progression-free survival (PFS) of the 40 patients was 1 7 months (range 1 0-29 months)and the median overall survival (OS)was 30 months (range 22-41 months).The objective response rate was 85% (no case with complete remission and 34 with partial remission).A majority of toxicities were grade I-II,mainly including anemia,neutropenia,nausea, vomiting and rash.Conclusion Alternate chemotherapy with first-line gefitinib yielded high remission rate and mild toxic responses in treating advanced non-small cell lung cancer with positive mutation of EGFR.关键词
晚期非小细胞肺癌/EGFR突变阳性/吉西他滨/顺铂/卡铂/吉非替尼Key words
Advanced non-small cell lung cancer/Positive mutation of EGFR/Gemcitabine/Cisplatin/Carboplatin/Gefitinib引用本文复制引用
江冠铭,贾筠,陈镜塘,吴依芬,谭钦全,卢志斌..化学治疗交替吉非替尼治疗 EGFR 突变阳性的晚期非小细胞肺癌的疗效和安全性[J].新医学,2015,(6):391-394,4.
